Tranexamic Acid for Knee Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is a prospective double-blind randomized controlled trial to evaluate the effect of extended oral TXA after primary total TKA on short-term and mid-term postoperative outcomes, including function, pain, and postoperative complications over a 24-month period, with evaluations at 6 weeks, 3 months, 12 months, and 24 months. Each group of 175 patients will receive either extended oral TXA 1.95g daily or placebo for 7 days postoperatively. Function will be assessed by Knee Injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR) scores measured at all post operative time points as well as range of motion (ROM) (measured at all visits).
Who Is on the Research Team?
Anna Cohen-Rosenblum, MD, MSc
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either extended oral TXA 1.95g daily or placebo for 7 days postoperatively
Follow-up
Participants are monitored for function, pain, and postoperative complications with evaluations at 6 weeks, 3 months, 12 months, and 24 months
What Are the Treatments Tested in This Trial?
Interventions
- Tranexamic acid
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Patients treated with tranexamic acid 1.95g per day for 7 days postoperative.
Patients treated with placebo daily for 7 days postoperative.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.